HIMS posted stellar Q1 FY 2025; growth fueled by ~2.4M subscribers and $84 average monthly revenue per user. Click here to ...

Yet, I assess that Viking Therapeutics’s main growth vector will likely be imputed to its ability to commercialize and ...

The MUSC Weight Management Center (WMC) is casting a lifeline to plus-sized individuals at wit's end with their apple cider ...

Drugmakers are offering the blockbuster medications at steep discounts to people willing to pay out of pocket.

Regional equity markets closed in positive territory on Tuesday, building positive momentum after a muted trading session on ...

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

Novo Nordisk NVO shares have gained 13.9% in the past month. Several factors related to the company’s pipeline, regulatory ...

While there isn’t a one-size-fits-all Wegovy diet, there are some key takeaways to keep in mind: It’ll take time to adjust to the lifestyle changes associated with weight loss medication.

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22.8 kilograms) over 72 ... taking Wegovy, the study found. Weight loss was about 6% ...

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22.8 kilograms) over 72 weeks ... 20% of their body weight on average, compared with a nearly ...

The momentum is now with Lilly. Visible Alpha, a data firm, expects its sales of obesity drugs to overtake Novo’s by 2027 (see chart 2). Lilly’s edge rests on a more effective drug, better execution, ...

You’ll attach new needles to the same pen each time ... for weight loss. Your prescribing doctor will get you started on a lower dose of Ozempic or Wegovy and slowly increase the dose over ...